Aclaris Therapeutics Inc
(NASDAQ:ACRS)
$0.86
-0.0182[-2.07%]
Last update: 7:56PM (Delayed 15-Minutes)
Get Real Time Here
$0.86
0[0.00%]
After-Hours
Open0.880Close0.875
Vol / Avg.2.619M / 3.831MMkt Cap60.919M
Day Range0.840 - 0.91152 Wk Range0.590 - 18.540

Aclaris Therapeutics Stock (NASDAQ:ACRS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$9.00

Consensus Price Target1

$15.44

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
51200

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Cantor Fitzgerald
  • Stifel
  • William Blair
  • Evercore ISI Group

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Aclaris Therapeutics

Upgrades (0)

Downgrades (3)

Initiations (6)

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
11/14/2023ACRSBuy Now
Aclaris Therapeutics
$0.86946.51%HC Wainwright & Co.
Raghuram Selvaraju
$43 → $9MaintainsBuyGet Alert
11/14/2023ACRSBuy Now
Aclaris Therapeutics
$0.86Cantor Fitzgerald
Louise Chen
DowngradeOverweight → NeutralGet Alert
11/13/2023ACRSBuy Now
Aclaris Therapeutics
$0.86132.56%Stifel
Alex Thompson
$20 → $2DowngradeBuy → HoldGet Alert
11/13/2023ACRSBuy Now
Aclaris Therapeutics
$0.86William Blair
Tim Lugo
DowngradeOutperform → Market PerformGet Alert
10/09/2023ACRSBuy Now
Aclaris Therapeutics
$0.864318.6%Cantor Fitzgerald
Louise Chen
→ $38ReiteratesOverweight → OverweightGet Alert
10/04/2023ACRSBuy Now
Aclaris Therapeutics
$0.864900%HC Wainwright & Co.
Raghuram Selvaraju
→ $43ReiteratesBuy → BuyGet Alert
10/03/2023ACRSBuy Now
Aclaris Therapeutics
$0.862458.14%Evercore ISI Group
Gavin Clark-Gartner
→ $22Initiates → OutperformGet Alert
09/19/2023ACRSBuy Now
Aclaris Therapeutics
$0.864318.6%Cantor Fitzgerald
Louise Chen
→ $38ReiteratesOverweight → OverweightGet Alert
09/19/2023ACRSBuy Now
Aclaris Therapeutics
$0.864900%HC Wainwright & Co.
Raghuram Selvaraju
→ $43ReiteratesBuy → BuyGet Alert
09/14/2023ACRSBuy Now
Aclaris Therapeutics
$0.862225.58%Stifel
Alex Thompson
$16 → $20MaintainsBuyGet Alert
08/08/2023ACRSBuy Now
Aclaris Therapeutics
$0.864900%HC Wainwright & Co.
Raghuram Selvaraju
→ $43ReiteratesBuy → BuyGet Alert
06/14/2023ACRSBuy Now
Aclaris Therapeutics
$0.864900%HC Wainwright & Co.
Raghuram Selvaraju
→ $43ReiteratesBuy → BuyGet Alert
03/07/2023ACRSBuy Now
Aclaris Therapeutics
$0.862341.86%Goldman Sachs
Corinne Jenkins
$25 → $21MaintainsBuyGet Alert
03/07/2023ACRSBuy Now
Aclaris Therapeutics
$0.863272.09%BTIG
Julian Harrison
$32 → $29MaintainsBuyGet Alert
03/07/2023ACRSBuy Now
Aclaris Therapeutics
$0.864900%HC Wainwright & Co.
Raghuram Selvaraju
$50 → $43MaintainsBuyGet Alert
02/24/2023ACRSBuy Now
Aclaris Therapeutics
$0.865713.95%HC Wainwright & Co.
Raghuram Selvaraju
→ $50Reiterates → BuyGet Alert
02/07/2023ACRSBuy Now
Aclaris Therapeutics
$0.864318.6%Cantor Fitzgerald
Louise Chen
→ $38Reiterates → OverweightGet Alert
12/14/2022ACRSBuy Now
Aclaris Therapeutics
$0.863272.09%Stifel
Alex Thompson
→ $29Initiates → BuyGet Alert
12/01/2022ACRSBuy Now
Aclaris Therapeutics
$0.862806.98%Goldman Sachs
Corinne Jenkins
→ $25Initiates → BuyGet Alert
Q

What is the target price for Aclaris Therapeutics (ACRS)?

A

The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $9.00 expecting ACRS to rise to within 12 months (a possible 946.51% upside). 18 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?

A

The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by HC Wainwright & Co., and Aclaris Therapeutics maintained their buy rating.

Q

When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.

Q

Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?

A

While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a maintained with a price target of $43.00 to $9.00. The current price Aclaris Therapeutics (ACRS) is trading at is $0.86, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.